
Everest Medicines' licensing partner, Calliditas Therapeutics, announced FDA approval for Nefecon® capsules, a groundbreaking treatment for primary immunoglobulin A nephropathy (IgAN) in adults at risk for disease progression. The FDA approval is based on a statistically significant benefit in estimated glomerular filtration rate (eGFR) over a two-year period. Nefecon® targets the origin of IgAN, reducing the production of pathogenic antibodies. Everest Medicines CEO Rogers Yongqing Luo expressed excitement about the FDA approval, highlighting plans to launch the treatment in China in Q1 2024, addressing the urgent need for IgAN patients in the country.
Like
Save
Share